

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/975,813	10/12/2001	Jeffrey A. Miller	DM-6907-A	1068
23914 75	590 06/30/2004		EXAMINER	
STEPHEN B. DAVIS BRISTOL-MYERS SQUIBB COMPANY			FRONDA, CHRISTIAN L	
PATENT DEPA		•	ART UNIT	PAPER NUMBER
P O BOX 4000			1652	
PRINCETON, NJ 08543-4000			DATE MAILED: 06/30/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	09/975,813	MILLER ET AL.	
Office Action Summary	Examiner	Art Unit	<u></u>
	Christian L Fronda	1652	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with th	e correspondence addre	ess
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION,  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS for cause the application to become ABANDO	e timely filed  days will be considered timely.  rom the mailing date of this comm  ONED (35 U.S.C. & 133).	nunication.
Status			
1) Responsive to communication(s) filed on	_•		
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.		
3) Since this application is in condition for allowan			erits is
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11,	453 O.G. 213.	
Disposition of Claims			
4)⊠ Claim(s) <u>1-52</u> is/are pending in the application.			
4a) Of the above claim(s) is/are withdraw	vn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) <u>1-52</u> are subject to restriction and/or e	lection requirement.		
Application Papers			
9) The specification is objected to by the Examiner	•		
10) The drawing(s) filed on is/are: a) acce	epted or b) objected to by the	e Examiner.	
Applicant may not request that any objection to the d	frawing(s) be held in abeyance. S	See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correction			• •
11) The oath or declaration is objected to by the Exa	aminer. Note the attached Office	ce Action or form PTO-	152.
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a a) All b) Some * c) None of:	priority under 35 U.S.C. § 119	(a)-(d) or (f).	
1. Certified copies of the priority documents	have been received.		
2. Certified copies of the priority documents	have been received in Applica	ation No	
3. Copies of the certified copies of the priori		ved in this National Sta	ge
application from the International Bureau	` ''		
* See the attached detailed Office action for a list of	of the certified copies not recei	ved.	
Attachment(s)			
)  Notice of References Cited (PTO-892)  ?)  Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summa Paper No(s)/Mail	* `	
Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date		Patent Application (PTO-152	2)
Delegational Trademost Office			

Art Unit: 1652

## **DETAILED ACTION**

## Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claim(s) 1- 25, 31, and 32, drawn to a peptide, classified in class 530, subclass 300.
  - II. Claim(s) 26, 27, and 43-48, drawn to a method for the determination of the presence of aggrecan-degrading metalloprotease activity using antibodies, classified in class 436, subclass 507.
  - III. Claim(s) 28, drawn to a method for the determination of ADMP activity by eluting a peptide from a reverse-phase HPLC column, classified in class 530, subclass 412.
  - IV. Claim(s) 29, 30, 34, and 36-48, drawn to a method for assaying compounds for activity against an ADMP, classified in class 435, subclass 18.
  - V. Claim(s) 33, 35, and 36-48, drawn to an assay for detecting ADMP activity, classified in class 435, subclass 7.1.
  - VI. Claim(s) 49, drawn to a method of use of an assy for detecting ADMP-generated aggreean fragments in culture media from tissue or cell cultures stimulated to induce aggreeanase-mediated degradation, classified in class 435, subclass 29.
  - VII. Claim(s) 50, drawn to a method of use of an assay for detecting aggrecanase-generated aggrecan fragments in biological fluids, tissue extracts or homogenates, serum or urine from patients with aggrecanase-associated diseases, classified in class 435, subclass 7.1.
  - VIII. Claim(s) 51, drawn to a method for diagnosing arthritic diseases in a mammal by monitoring ADMP-generated aggrecan fragments, classified in class 436, subclass 509.
  - IX. Claim(s) 52, drawn to a method for diagnosing a disease in a mammal characterized by overproduction or up-regulated production of an ADMP, classified in class 436, subclass 506.

Art Unit: 1652

2. The inventions are distinct, each from the other because of the following reasons: Inventions of Groups II-IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The processes of Groups II-IX are distinct both physically and functionally; require different process steps, reagents, and parameters; and have different purposes.

Inventions I and II-IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using the peptides in a process to make antibodies to said peptides.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re

Art Unit: 1652

Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM - 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**CLF** 

CUTTOMARIA DE LA COMPAÑA DE LA